The OneTouch Reveal® Plus app, powered by BlueStar®, is indicated for use by patients aged 18 and older who have Type 1 or Type 2 diabetes and their healthcare providers. The app is not intended to replace the care provided by a licensed healthcare professional. The app should not be used by patients with gestational diabetes or patients using an insulin pump. BlueStar® is a Welldoc, Inc. patented system. The OneTouch Reveal® Plus app is manufactured by Welldoc, Inc.
1Carls G, et al. Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes Ther. 2017 Aug;8(4):863-873. (doi: 10.1007/s13300-017-0280-5) Epub 2017 June 23. Based on recent National Health and Nutrition Examination Survey (NHANES) from 2007-2014 with data from 2677 adults.
2Evans JMM, et al. Self-monitoring of blood glucose in type 2 diabetes: patients’ perceptions of ‘high’readings. Diabetes Res Clin Pract 2013; 102 (1):e5-e7. doi: http://dx.doi.org/10.1016/j.diabres.2013.07.011. Based on results of 207 non-insulin using patients, 28% correctly identified a blood glucose reading of 393>235 mg/dL as a high result.
3Polonsky Wh, et al. A survey of blood glucose monitoring in patients with type 2 diabetes: are recommendations from health care professionals being followed? Curr Med Res Opin 2011;27 (suppl 3):31-37. Based on patient-reported use of SMBG data, 54% of 320 patients said they take no action in response to highs and lows.